Histone deacetylases (HDACs) play critical roles in silencing tumor suppressor genes. HDAC inhibitors reactivate tumor suppressor genes and inhibit tumor cell growth in vitro and in vivo, and several HDAC inhibitors are currently being evaluated in clinical trials for cancer therapy. A comprehensive analysis of proteins regulated by HDAC inhibitors would enhance our ability to define and characterize their essential therapeutic targets. Here, we employed stable isotope labeling with amino acids in cell culture-based quantitative proteomics to identify acetylated proteins in human breast cancer cells. Treatment with the clinically relevant HDAC inhibitor, suberoylanilide hydroxamic acid (vorinostat), induces lysine acetylation of 61 proteins in MDA-MB-231 human breast cancer cells. Suberoylanilide hydroxamic acid not only induces lysine acetylation in chromatin-associated proteins, but also acetylates previously unrecognized nonhistone proteins, including transcriptional factors and regulators, chaperones, cell structure proteins, and glycolytic enzymes in a time-dependent manner. Knowledge of the full repertoire of acetylated proteins will provide a foundation for further defining the functions of HDACs in cancer cells.
Introduction
Lysine acetylation in histones is a key mediator of gene transcription. Acetylated histones usually create transcriptionally active euchromatin, whereas deacetylated histones dictate transcriptionally silent heterochromatin [1] .
This reversible process is regulated by the balance between histone acetyltransferases and histone deacetylases (HDACs). Three major classes of mammalian HDACs have been extensively described. Class I and II HDACs require zinc to hydrolyze the acetyl-lysine amide bond, which is a critical step for enzyme activity. Class III HDAC enzymatic activity depends on the cofactor nicotinamide adenosine dinucleotide. In general, class III HDAC activity is not affected by class I and II HDAC inhibitors [1, 2] . Recent advances have shown that cancer development is intimately associated with aberrant HDAC expression. It has been recognized that dysregulation of HDAC activity can silence tumor suppressor gene transcription leading to increased likelihood of neoplastic initiation and progression [3] [4] [5] . Given the important role of HDACs in tumorigenesis, a number of class I and II HDAC inhibitors have been developed and studies have demonstrated that inhibition of HDAC activity leads to hyperacetylation of histones followed by transcriptional activation of certain tumor suppressor genes through reorganization of transcriptionally silent heterochromatin [1] . In various transformed tumor cells, HDAC inhibitors induce cell cycle arrest, cell differentiation and/or apoptotic cell death [2] . Since HDAC inhibitors possess potent antitumor activity with tolerable side effects, several HDAC inhibitors are currently being evaluated in the clinic [2, 6] . For example, LBH589, a cinnamyl hydroxamic acid derivative, inhibits class I and II HDAC activities and is in phase II clinical trials. Suberoylanilide hydroxamic acid (SAHA) (vorinostat), a second-generation hydroxamate HDAC inhibitor, has entered the clinic for treatment of refractory cutaneous T-cell lymphoma.
In addition to the well-documented effects of HDAC inhibitors on epigenetic gene regulation, the scope of lysine acetylation extends to multiple regulatory proteins and diverse signaling pathways [1, 2] . Recently, global analyses of lysine acetylation in response to HDAC inhibitors have been initiated, but only a few studies have been reported [7] [8] [9] . By using two-dimensional electrophoresis followed by peptidemass fingerprinting, Iwabata et al. [7] described organ-specific distribution of acetylated proteins in mice. More recently, immunoaffinity purification of acetylated peptides followed by nano-HPLC/MS/MS has been used to profile acetylated proteins in HeLa cells and mouse liver mitochondria [8] . High-resolution MS was used to quantify acetylation changes in response to treatment with HDAC inhibitors SAHA and MS-275 [9] . However, dynamic alteration of lysine acetylation profiles in response to HDAC inhibitors has not yet been reported. Thus, development of a novel method of analysis applied to a cancer cell culture model would greatly enhance our ability to define and characterize the essential therapeutic targets of HDAC inhibitors. We used a stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomic strategy to achieve this goal.
The SILAC-based quantitative proteomic method utilizes stable isotopes to label cellular proteins. We have successfully applied SILAC to the study of tyrosine phosphorylation [10, 11] . Herein, we describe an analysis of the acetyl-lysine proteome to identify and quantify dynamic alterations of lysine acetylation in SAHA-treated breast cancer cells. Our results demonstrate that this approach is a powerful method to identify HDAC targets. Data generated from this study will facilitate the future characterization of the biological significance of lysine acetylation in cancer cells.
Materials and methods

Cell culture and SILAC-labeling
MDA-MB-231 breast cancer cells were grown in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 5% FBS (HyClone, Logan, UT, USA) and 2 mM L-glutamine at 371C in a humidified incubator with 5% CO 2 -95% air atmosphere. The cells grown in natural arginine and lysinecontaining DMEM were used as a control (normal Arg/Lys). For SILAC labeling, arginine-and lysine-free DMEM were obtained from Invitrogen. The Arg/Lys-free DMEM was supplemented with light ( 13 C 6 Arg/D4 Lys; 16 Da and 1 4 Da shift for labeled arginine-and lysine-containing peptides, respectively), and heavy ( 13 C 6 15 N 4 Arg/ 13 C 6 15 N 2 Lys; 110 Da and 18 Da shift for labeled arginine and lysinecontaining peptides, respectively) peptides. The cells were adapted for at least five generations before use in experiments. Detailed SILAC methods used were as described in our previous studies [12] .
Lysine acetylation immunoprecipitation
A measure of 5 Â 10 7 cells from each ''state'' were treated with 10 mM SAHA for 24 and 48 h. The cells were lysed in a lysis buffer (10 mM Tris, pH 7.4, 10 mM KCl, 1.5 mM MgCl 2 , and protease inhibitor mixture tablets (Roche, Indianapolis, IN, USA)), briefly sonicated, and then collected by centrifugation. Protein concentrations were measured by the Lowry method (BioRad, Los Angeles, CA, USA), and equal amounts of protein from lysates of each state were mixed together. Lysine acetylation immunoprecipitation was performed using antiacetylated antibodies (ImmuneChem, Burnaby, British Columbia, Canada) coupled to protein A agarose at 41C overnight with constant mixing. The beads were then washed three times in 1 mL cell lysis buffer followed by boiling with SDS-PAGE sample buffer, and the proteins were stained using colloidal Coomassie stain before gel digestion.
In-gel digestion and LC-MS/MS analysis
The gel bands were excised and subjected to in-gel trypsin digestion. Extracted peptides were dried down using speedvac, reconstituted in 10 mL 1% acetic acid and 3% ACN, and analyzed by LC-MS/MS using a reversed phase-LC interfaced with a quadrupole TOF mass spectrometer (Micromass Q-TOF API-US mass spectrometer). The reversed phase-LC system consisted of trap column (75 mm Â 3 cm, C18 material 5-10 mm, 120 Å , LC packing) and analytical column (75 mm Â 10 cm, C18 material 5 mm, 120 Å , LC packing). The peptides were separated using an organic solvent gradient (0-60%) containing 0.1% formic acid and ACN. The MS spectra were acquired in a datadependent manner targeting the four most abundant ions in the survey scan and excluded for MS/MS scan for 60 s. Peptide and protein identification was done using the MASCOT algorithm (version 2.1.04) to search the spectra against the RefSeq (release 22) human protein database. The tolerance used for peptide ions was 0.2 Da and for fragment ions was 0.3 Da. Peptides with a minimum MASCOT score of 25 were manually validated and used for generating the list of identified proteins. Relative abundance of proteins was calculated using MSQuant software (version 1.4.3a39) downloaded from http://msquant.sourceforge.net [13] . The fold changes were expressed as mean values. Mass spectral data were processed as individual peak list files for every MS/MS spectra and subsequently merged using a Perl script to retain the scan number. The resulting mascot readable file was used for mascot search. The MASCOT search results were parsed with LC-MS/MS instrument data file using MSQuant. The new_MSQ_quantitationMo-des.xml files were modified to read the mascot output files and identify the correct light, medium, and heavy isotopic MS peaks. The quantitation data were also verified by manual inspection of heavy-and light-peptide-derived MS and MS/MS spectra in MSQuant.
Confirmation of acetylated proteins identified from proteomic analysis
Cells were grown in normal DMEM medium as described above. After SAHA treatment, whole cell lysates were prepared by lysing the cells with 1% SDS and 10 mM TrisHCl (pH 7.4). Immunoprecipitations were performed with clear supernatant using antibodies to elongation factor-1a (EF-1a), enolase-1, 14-3-3g, helicase-like transcription factor (HLTF), and Hsp90 from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antiacetylated lysine antibody (ImmuneChem) was used for immunoblotting for detection of lysine acetylation.
Results
SILAC-labeled MDA-MB-231 cells
Cells were split into three sets and cultured in the presence of DMEM media containing (i) natural L-arginine and L-lysine, (ii) light 13 C 6 -L-arginine and 2 H 4 -L-lysine or (iii) heavy 13 C 6 15 N 4 -L-arginine and 13 C 6 15 N 2 -L-lysine, respectively. The natural amino acid-containing cells were treated with vehicle (DMSO) as a control, while light and heavy SILAClabeled cells were treated with 10 mM SAHA for 24 and 48 h, respectively. We have previously shown that labeled cells showed no change in biological phenotype as compared with the nonlabeled cells [12] . To confirm this conclusion in breast cancer cells, Western blot analysis was used to examine candidate proteins known to be expressed in MDA-MB-231 cells. For example, the labeled and nonlabeled cells show similar basal DNMT1 levels ( Fig. 1A) and treatment with SAHA has equivalent inhibitory effects on levels of DNMT1 protein in both labeled and nonlabeled amino acids. To evaluate effect of HDAC inhibitors on lysine acetylation, acetylated proteins were separated by SDS-PAGE, transferred to a membrane, and detected by using antiacetyl-lysine antibodies. Figure 1B shows that treatment of MDA-MB-231 cells with HDAC inhibitors, SAHA and LBH589, leads to modifications in lysine acetylation in numerous proteins by 24 h.
Identification of acetylated proteins
To perform SILAC-based quantitative proteomic analysis, equal amounts of cell lysates from control, 24 h SAHAtreated and 48 h SAHA-treated samples were combined, and acetylated proteins were immunoprecipitated using antiacetyl-lysine antibody (Fig. 1C) . The immunoprecipitation complexes were separated by SDS-PAGE, and visualized by Coomassie Blue staining (Fig. 2, left panel) . In parallel, the same immunoprecipitated proteins were immunoblotted, and acetylated proteins were detected using antilysine acetylation antibodies. Figure 2 (right panel) shows that the antibody can detect multiple lysine acetylation targets ranging from 11 to 200 kDa, suggesting that the acetylated proteins can be effectively immunoprecipitated. To proceed to MS/MS analysis, the gel bands were excised and digested with trypsin before LC-MS/MS. Peptide sequences were obtained from the MS/MS spectra, and the MASCOT search algorithm was performed to identify peptide candidates from the human protein database. In the MS spectra, second-state-labeled Lys ( 2 H 4 -Lys) and Arg ( 13 C 6 -Arg) show 4-and 6-Da shifts, respectively, while heavy labeled Lys ( 13 C 6 15 N 2 -Lys) and Arg ( 13 C 6 15 N 4 -Arg ) represent 8-and 10-Da shifts, respectively. The ratio between the intensity of the labeled (light or heavy) peptide peak divided by the intensity of the unlabeled peptide peak is used for quantification of lysine acetylation. Figure 3 shows representative MS/MS spectra of peptides derived from enolase-1, Hsp90, EF-1a, and 14-3-3-g. As an example, an enolase-1 peptide-containing TIAPALVSK showed a 2.5-fold difference in the intensity of the light Lys peaks and a 5.4-fold difference in the intensity of the heavy Lys peaks as compared with nonlabeling peptides (control sample), indicating that lysine acetylation in enolase-1 is elevated 2.5-and 5.4-fold after 24 and 48 h of treatment, respectively. Using a predetermined cutoff of 1.5-fold, we identified 61 proteins whose lysine acetylation was increased after 24 h and/or 48 h of SAHA treatment (Table 1) . A literature search showed that 14 of these proteins have been previously reported to be acetylated proteins, whilst the remaining 47 proteins are newly described to be acetylated in human breast cancer cells.
SAHA induction of lysine acetylation occurs in a time-dependent manner
Lysine acetylation is a reversible process, and dynamic alterations of lysine acetylation are likely to contribute to differences in gene transcription and biological outcomes. Our study design afforded us the opportunity to monitor alterations in the profile of lysine acetylation at two time points during SAHA treatment of MDA-MB-231 cells. As summarized in Table 1 , only six proteins are acetylated after 24 h of SAHA treatment, principally histones (H2 and H3 family). We found that 19 proteins are persistently acetylated after both 24 and 48 h of SAHA treatment. These include acetylated histones (H1, H4), chaperones (Hsp70 and Hsp90), and transcription factors/regulators (translational elongation factors, 14-3-3 and sequestosome 1). We also observed that the majority of proteins (n 5 36) had unaltered lysine acetylation at 24 h, and showed increases in acetylation after 48 h of SAHA treatment. Many of these proteins are involved in cell structure maintenance, chromosome and transcription regulation. As previous reports indicate that SAHA reactivates silent tumor suppressor genes, and induces cell apoptosis by 48 h in vitro [14, 15] , this therapeutic effect is correlated with the prolonged increase in acetylated histones, transcription factors/regulators, and cell structure maintenance proteins, suggesting that sustained lysine acetylation contributes to the pharmacological effects of SAHA over time.
Verification of SILAC-based proteomic analysis
To validate our findings, selected candidate proteins were immunoprecipitated, and their lysine acetylation status was examined by immunoblotting. As shown in Fig. 4 , this independent analysis confirmed the MS/MS results in non-SILAClabeled cells. For example, we confirmed that EF-1a, Hsp90, 14-3-3-g, and enolase-1, were hyperacetylated at 24 and 48 h in SAHA-treated cells. We also confirmed that lysine acetylation in HLTF was markedly increased at 24 h of SAHA treatment, whereas total HLTF protein levels remained unchanged. Collectively, these data confirm the accuracy of the mass spectrometric method for identification of acetylated proteins.
Discussion
Prolonged SAHA treatment can lead to a significant accumulation of lysine-acetylated proteins
Given the extensive roles for HDACs in gene transcription, DNA repair and signal transduction during neoplastic transformation, a global screening of lysine acetylation is essential for understanding the molecular mechanisms of HDAC inhibitors in cancer therapy. Recently, several studies profiled lysine acetylation in human tumor cells and animal tissues. Iwabata et al. [7] generated antiacetyl-lysine mouse monoclonal antibodies and identified organ-specific distribution of acetylated proteins in mice. They found that a-enolase, NF-L, Hsc70, a-tubulin, and b-actin are specifically acetylated in mouse brain, whereas a-actin and creatine kinase can be lysine-acetylated in mouse skeletal muscle. Kim et al. [8] demonstrated that treatment of HeLa cells with a combination of class I, II, and III HDAC inhibitors (trichostain A and sirtinol) for 24 h led to identification of 75 acetylated proteins (37 in the cytosol and 38 in the nucleus). Inhibition of HDAC induces acetylated proteins in mouse liver mitochondrial protein, suggesting that HDACs play key roles in regulation of activities of metabolic enzymes [8] . Most recently, Mattias Mann's group found that lysine acetylation not only alters chromatin remodeling and nuclear transcription, but also regulates cytoplasmic protein-protein interaction. For example, acetylated 14-3-3 disrupts interaction of 14-3-3 with cyclindependent kinase Cdc28 [9] . Although these studies identify a broad scope of lysine acetylation, the dynamic alterations of lysine in response to clinically relevant HDAC inhibitors in cancer cells have not been investigated. We observed 36 proteins that were lysine acetylated only after 48 h of SAHA treatment, which include those controlling cell structures (tubulin) as well as chaperone proteins. We also found that SAHA treatment led to persistent lysine acetylation of 19 proteins after 24 and 48 h. Thus, SAHA treatment enhances lysine acetylation in time-dependent manner that is distinct for different sets of proteins. This is consistent with the clinical observation that an increase in acetylated histones can be maintained over a longer period of SAHA treatment coincident with antitumor activity of SAHA that can be achieved over time [16] . The time-dependent acetylation may be important in regulation of protein functions. It has been known that HDAC4 and HDAC5 interact with ankyrin-repeat domain protein (ANKRA), the aryl hydrocarbon receptor repressor-binding protein, leading to inhibition of aryl hydrocarbon receptor repressor activity [17] . The ANKRA inhibitory effect can be reversed by treatment with HDAC inhibitors [17] . We identified that SAHA induces acetylation of ANKRA at 24 h but not 48 h, suggesting that early lysine acetylation may be important in inhibition of the ANKRA biological function. ATP-dependent chaperone Hsp90a interacts with multiple oncogenic proteins to promote tumor cell proliferation and invasion [18] [19] [20] . We observed that Hsp90 is persistently acetylated for up to 48 h. The prolonged acetylation inhibits ATP-dependent Hsp90 chaperone function leading to degradation of DNMT1, a key oncogenic protein in maintaining DNA methylation [21] . Furthermore, we showed that acetylation of mitochondrial translational release factor 1-like only occurs after 48 h of SAHA treatment. Mitochondrial translational release factor 1-like is an essential mammalian mitochondrial factor involved in the initiation and elongation phases of translation, and this delayed posttranscriptional modification (PTM) implicates a role of HDACs in the translational termination process in mammalian mitochondria.
Previously unrecognized lysine acetylation targets have been identified by using SILACbased quantitative proteomic analysis
Our study has shown that a therapeutically useful HDAC inhibitor, SAHA, induces lysine acetylation of 61 proteins in MDA-MB-231 human breast cancer cells. These findings suggest that lysine acetylation in histone and nonhistone proteins contribute to the actions of HDAC inhibitors. Among these, it is noteworthy that Hsp70, Hsp90 (a and b), tubulin (a and b), and triosephosphate isomerase 1 have been shown to be lysine acetylated using the SILAC methodology. Identification of these proteins through our proteomic analysis validates our proteomic approach since these proteins are known to be targets from previous proteomic assays [7] [8] [9] . Most importantly, we identified previously unrecognized HDAC targets, including chromatin-associated proteins, transcriptional factors, transcriptional regulators, chaperone proteins, structural proteins, cell cycle regulators, and tumor antigens. For example, of the acetylated chaperones, we identified lysine acetylation on chaperone proteins including chaperonin-containing TCP1 (subunit 3 isoform c) and three subunits of Hsp70 family. Given the critical role of acetylated Hsps in the regulation of oncogenic protein stability and tumor cell invasion [21] [22] [23] [24] , identification of these members of the chaperone protein family will enhance our ability to further characterize their roles in signal transduction and protein stability. Additionally, several novel modifications of chromosome-associated proteins were also identified. These include structural maintenance of chromosomes 3, centrosomal proteins (170 and 290 kDa), and isoform 2 of minichromosome maintenance protein 8. Data generated from our study could greatly advance our understanding of the clinical consequences of SAHA treatment on different cellular pathways. Proteomics 2010, 10, 1029-1039 
SAHA induces lysine acetylation in diverse cellular processes
Our data demonstrated that lysine acetylation can occur in several enzymes involved in glucose metabolism, including dihydrolipoamide S-succinyltransferase, enolase-1, glyceraldehyde 3-phosphate dehydrogenase, lactate dehydrogenase A, and PK3 (pyruvate kinase 3). Lysine acetylation is known to affect these enzyme activities. For example, acetylation of glyceraldehyde 3-phosphate dehydrogenase can decrease the key reaction in glycolysis in some types of cancer cells [25] .
Other studies have reported that a combination of class I, II, and III HDAC inhibitors can target cytosolic metabolic enzymes such as enolase 1 [7, 8] and our studies add strong evidence that glycolytic metabolism is connected to class I and II HDACs. It is conceivable that increased lysine acetylation may alter activities of key metabolic enzymes and affect energy homeostasis in response to nutrients in mammals. Dynamic modification of microfilaments by HDACs has been shown to increase cell motility [26] . Our results identified the previously recognized HDAC targets, tubulin (a and b), and actin [8, 27, 28] . We also identified previously unrecognized HDAC targets involved in signal transduction. One representative class is the Rho-specific guanine nucleotide exchange factors, which can activate Rho family GTPases, and is required for tumor cell transformation [29] . Mutant or acetylated Rho family proteins may impede their function, and alter cytoskeleton dynamics in transformed cells [8, 29] . HDAC inhibition also targeted annexin A2, a member of the annexin family of Ca 21 -dependent phospholipid and membrane binding. As annexin A2 functions as a substrate for protein kinases and mediates cell proliferation, differentiation, inflammation, and cytoskeletal interactions [30, 31] , its acetylation may represent a novel mechanism for regulation of its function.
Transcription factors and regulators are the most prominent proteins modulated by lysine acetylation. The nuclear receptor ERb was acetylated in the ERa negative human breast cancer cell line MDA-MB-231. ERb belongs to ligand-regulated transcription factors, and can form functional homo-or heterodimers with ERa that either enhance or antagonize estrogen response in ER-positive tissues [32] . Understanding that ERb is an acetylation target may help further determine its role in breast cancer.
14-3-3 Proteins belong to a family of conserved regulatory molecules, which can bind to HDAC 4 and 5 and inhibit HDAC activity in the cytoplasm [33] . 14-3-3 isoforms (g and z) are known to be expressed in breast cancer cells, and they bind to the tumor suppressor, tuberin, and negatively regulate AKT signaling [34, 35] . Aside from this, very little is known regarding the PTM of 14-3-3 in human cancer cells and our studies show that 14-3-3 is acetylated in SAHA-treated cells.
In summary, our data provide for the first time a comprehensive assessment of alterations in the lysine proteomic profile in MDA-MB-231 cancer cells treated with an FDA-approved HDAC inhibitor, SAHA. This analysis shows that SAHA targets proteins that function in multiple histone and nonhistone-based cellular pathways. They include previously unrecognized lysine acetylation targets in the transcription factors/regulators, chromatin structure, cytoskeletal proteins, cell cycle regulators and tumor antigen families. Our studies also suggest that prolonged treatment with SAHA can sustain lysine acetylation, an effect that may be critical for the full therapeutic effect of SAHA in cancer therapy. Functional characterization of these acetylated proteins in signal transduction is under way, and may help to elucidate novel mechanisms that underlie the biological effects of HDAC inhibition in cancer therapy.
